Medlive Technology Co., Ltd. (HK:2192)
:2192
Want to see HK:2192 full AI Analyst Report?
Top Page
Medlive Technology Co., Ltd.
(2192)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$9.50
▼(-3.36% Downside)
Action:DowngradedDate:04/25/26
The score is driven primarily by strong financial fundamentals—especially high profitability and very low balance-sheet risk—partly offset by the 2025 revenue decline and weaker cash conversion. Technicals are a headwind due to a clear downtrend versus key moving averages, while valuation is moderately supportive with a reasonable P/E and a ~3.2% dividend yield.
Positive Factors
Conservative balance sheet (minimal debt)
Very low leverage materially reduces financial risk and gives Medlive durable flexibility to fund operations, invest in product development, or pursue strategic M&A without creditor pressure. This conservative capital structure supports resilience across cycles and underpins partner confidence.
Negative Factors
Material revenue decline in 2025 (-24%)
A 24% top-line contraction represents a significant, lasting risk: it interrupts growth momentum, erodes operating leverage, and may signal client loss or market-share pressure. Sustained revenue weakness would limit reinvestment capacity and force reliance on cost cuts or strategic pivots to restore growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet (minimal debt)
Very low leverage materially reduces financial risk and gives Medlive durable flexibility to fund operations, invest in product development, or pursue strategic M&A without creditor pressure. This conservative capital structure supports resilience across cycles and underpins partner confidence.
Read all positive factors
Medlive Technology Co., Ltd. (2192) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.40B
Dividend Yield2.72%
Average Volume (3M)1.46M
Price to Earnings (P/E)19.6
Beta (1Y)1.31
Revenue Growth15.04%
EPS Growth5.57%
CountryHK
Employees747
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.27
Shares Outstanding739,958,740
10 Day Avg. Volume901,132
30 Day Avg. Volume1,461,578
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.31
Price to Sales (P/S)10.21
P/FCF Ratio52.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.10Price Target Upside33.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.48
Revenue Forecast (FY)HK$753.56M
Medlive Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, ...
How the Company Makes Money
Medlive generates revenue primarily by monetizing its online physician platform and related digital healthcare infrastructure. Key revenue streams include: (1) digital marketing and promotion services for pharmaceutical and medical device companie...
Medlive Technology Co., Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
92
Very Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 625.54M | 558.46M | 412.00M | 314.05M | 284.44M |
| Gross Profit | 360.20M | 327.22M | 251.34M | 212.74M | 200.73M |
| EBITDA | 185.26M | 121.35M | 262.86M | 144.56M | 76.61M |
| Net Income | 325.69M | 315.15M | 242.30M | 117.32M | 40.62M |
Balance Sheet | |||||
| Total Assets | 5.16B | 5.11B | 4.89B | 4.60B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 4.15B | 4.40B | 4.22B | 3.91B |
| Total Debt | 10.11M | 22.63M | 8.19M | 11.26M | 13.17M |
| Total Liabilities | 230.01M | 253.56M | 248.61M | 171.31M | 143.37M |
| Stockholders Equity | 4.87B | 4.80B | 4.60B | 4.40B | 3.95B |
Cash Flow | |||||
| Free Cash Flow | 121.70M | 87.44M | 69.34M | 69.70M | 42.47M |
| Operating Cash Flow | 134.54M | 108.32M | 101.87M | 77.19M | 44.43M |
| Investing Cash Flow | 220.68M | 111.02M | -634.95M | -3.59B | -50.54M |
| Financing Cash Flow | -201.45M | -197.89M | -133.13M | -22.38M | 3.79B |
Medlive Technology Co., Ltd. Technical Analysis
Neutral
9.83
Price Trends
9.05
Positive
9.83
Negative
11.55
Negative
Market Momentum
0.02
Negative
57.31
Neutral
83.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Neutral. The current price of 9.83 is above the 20-day moving average (MA) of 8.51, above the 50-day MA of 9.05, and below the 200-day MA of 11.55, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 83.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2192.
Medlive Technology Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.40B | 19.61 | 6.83% | 2.72% | 15.04% | 5.57% | |
67 Neutral | HK$64.19B | 6.62 | 7.64% | 2.67% | 3.11% | 25.08% | |
66 Neutral | HK$1.62B | -231.76 | 4.85% | 3.81% | -10.71% | -87.93% | |
60 Neutral | HK$628.56M | 7.33 | 7.59% | 8.03% | -1.09% | -13.07% | |
57 Neutral | HK$57.70B | 7.82 | 8.62% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$443.97M | -0.61 | -66.54% | ― | -53.49% | -68.66% |
* Healthcare Sector Average
HK:2192
Medlive Technology Co., Ltd.
8.66
-3.08
-26.24%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.70
1.47
14.39%
HK:1099
Sinopharm Group Co
18.78
1.15
6.50%
HK:9955
ClouDr Group Limited
0.70
-0.40
-36.36%
HK:1931
IVD Medical Holding Limited
0.94
-0.72
-43.37%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.82
-1.44
-19.83%
Medlive Technology Co., Ltd. Corporate Events
Medlive Sets 2026 AGM to Approve Dividend, Board Slate and Capital Mandates
Apr 21, 2026
Medlive Technology Co., Ltd. has convened its annual general meeting for 15 May 2026 in Beijing, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend. The meeting...
Medlive Technology Delivers Double-Digit Revenue Growth in 2025 on Precision Marketing Strength
Mar 26, 2026
Medlive Technology reported solid growth for the year ended 31 December 2025, with revenue rising 15.0% year-on-year to RMB642.2 million, driven mainly by a 16.0% increase in its core precision marketing and corporate solutions segment. Gross prof...
Medlive Technology Declares Final 2025 Dividend for Hong Kong Shareholders
Mar 26, 2026
Medlive Technology Co., Ltd. has proposed a final ordinary dividend of RMB 0.1435 per share for the financial year ended 31 December 2025, equivalent to HKD 0.1629 per share based on an exchange rate of RMB 1 to HKD 1.1352. The payout, subject to ...
Medlive Moves to Modernize Governance With Paperless, Digital Shareholder Framework
Mar 26, 2026
Medlive Technology Co., Ltd. plans to revise its existing memorandum and articles of association to align with recent changes to Hong Kong’s Listing Rules, focusing on expansion of the paperless listing regime. The proposed changes include a...
Medlive Technology Sets March 26 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Medlive Technology has scheduled a board meeting for 26 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the recommendation and payment of a final dividend, signaling a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.